Dharmacon RNAi Technology Selected by Genentech to support Drug Discovery Research

07-Feb-2005

Dharmacon, Inc. announced that Genentech, Inc. has selected Dharmacon's advanced RNAi technology for use in its drug discovery and development research. Under an agreement between the two companies, Dharmacon will supply Genentech with a range of siRNA reagents including Dharmacon's Human Druggable Genome library, which focuses on those genes that are considered potential targets for therapeutics.

"We think it is fitting that Dharmacon, a pioneer in RNAi research, has been selected by Genentech, one of the world's leading biotechnology companies, to supply advanced siRNA products and technology for its drug discovery research programs, " said Leland Foster, president and chief executive officer of the Biosciences group of Fisher Scientific International Inc. "We believe this agreement is further indication that Dharmacon's SMARTselection and SMARTpool technologies are a preferred gene-silencing platform for drug discovery research among leading pharmaceutical and biotechnology companies. Dharmacon's continued leadership in the RNAi field and the exceptional potency and specificity of our siRNA reagents make us the supplier of choice for researchers utilizing RNAi technology to accelerate drug discovery."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances